Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi guys,
I rarely post. I’ve been a shareholder since 2013 ! Been through Reverse splits, and many lows! I’ve been extremely patient with the company because I believe in management.
I’ve been in the red most of the time, but have kept averaging down. I feel that it’s time for payback! There are no guarantees here, but if any of the potential news materialize, expect an aggressive move up.
Remember: where there is smoke, there is fire!
C’mon SUNSHINE !!!!
Good call Rando:)
They haven’t done everything yet...
They haven’t secured financing! That is the main obstacle here imo
This is our last chance ...
I’m hoping, but not holding my breath! Once RS goes through, and IF we do not have SOLID news, thus thing will drop and never come back. We need news either on:
1-Positive xenograft studies
2- Official mention that we are now heading into clinical trials , with financial backing from a third party.
FYI, we are NOT in clinical trials right now. These are Preclinical trials btw. The company hasn’t been able to enter clinicals due to lack of funding. It is very expensive.
If things do not get materialized within I would say 3 more months, then the stock will drop for good. If any of the news I’m hoping for do get announced, then the SP will move up aggressively to new highs.
This is hilarious...
What kind of a trading pattern is this? Pure manipulation.
What do you guys make out of this?
Is that a legit buy order at the end?
31 million shares bought? How does the ask not go up? Can someone please explain...
Thank you
So these aren’t regular traders buying and selling?
And when you say dilution, how is it diluted exactly if market makers are buying or dumping to themselves?? Sorry ... don’t know how this works exactly...
So these aren’t regular traders buying and selling?
And when you say dilution, how is it diluted exactly if market makers are buying or dumping to themselves?? Sorry ... don’t know how this works exactly...
I just don’t understand.
These trades ( buys or sells) are purely speculative / gambling / quick buck ... call it what you want imo.
Who in there right mind would sell at this point, without knowing the outcome of the xenograft results? Trying to figure this out. Any educated input would be appreciated .
Ok I see it under Officer rémunérations...
Q:
Where do you see their “unjustified” salaries?
Tic toc...tic toc...
Let’s wait and see. We should receive an update on clinical tests within a month. Positive news will aggressively drive the SP upward (IMO)
Any educated guesses as to why the sudden volume?
Can someone pls educate me ? What is a rw? What does this entail?
Thanks
Pennyboy20,
Now that is assuming they sell shares to GHS at these prices. They could HOPEFULLY wait and release a solid news which could drive the price much higher then these levels, and THEN sell shares...at a higher price. Correct?
Quite frankly, I’m not too sure what to make out of this.
Can’t believe we saw trips ... haven’t see these lows ever (I’ve been holding since 2012...averaged down tremendously last couple of week).
Can someone who understands the latest press releases regarding financing pls explain if this 10M $ is actually a done deal, and if not how does this deal work? Is it beneficial for Sunshine?
Trying to stay positive, but these levels are disgusting. Who would sell here?
Question:
From what I can gather, the 10 M$ will be given to Sunshine in exchange to shares that the company will give to GHS. Sunshine will be giving a maximum of 233 million shares in exchange to the $. GHS in turn can do whatever they want with the shares . Is this correct?
If so, it is beneficial for Sunshine to give the shares only when share price is much higher then it actually is. I would assume and hope that Dr Slilaty has a plan in place to drive the stock price much higher than these levels.
I would appreciate anyone with full understanding of the loan terms to confirm if my understanding is correct.
Thank you.
Agreed.
I certainly hope not duderaja. The company did indeed go through tough times, I.e finding financing took very long. But things are progressing nicely, and in the BIO industry 5-6 years is not very long.
This particular stock can move up very aggressively if and when decent news/progress is announced.
Quote:
The stock market is a market where a transfer of shares takes place from the non-patient to the patient...
Warren Buffet
I happen to trust the management team. I’ve spoken to them in the past, and they certainly are honest, intelligent people. Look up Dr Slilaty, and read his resume. I’ve been a shareholder for over 5 years, so believe me that I have spoken to the Dr on a few occasions, and I trust him completely.
Patience will pay off...that’s all I can tell you. We are almost there:)
Can someone pls explain to me what a form S1 is, and why is it bad?
Where do you read that a reverse split needs to be done for the financing?
Patience is a virtue.
Management has a clear plan, and financing has given them the long waited green light. These levels will soon disappear...expect aggressive move up from here IMO upon news / update regarding the implementing of their plans.
Hi guys,
What does Level 2 look like?
Thanks
Question:
In one of their previous News Releases, the company mentioned that they had extended their agreement with Jitney Financial for the private placement of 8,000,000 $US ( 400,000,000 shares at 0.02 USD) until August 31st. Should we be expecting news early September regarding this financing? If Jitney does not succeed to raise all this capital, and raises say 50% of the total amount ( 4,000,000$ US), wouldn’t that still be decent news and shouldn’t that be announced in a PR?
This I believe is the key to the success of our company; we need this financing.
My other question is: who would buy shares of SBFM for 0.02$ if it is trading on the open market for a tenth of that price?
Appreciate a response.
My position: Long. I expect big things from Sunshine. I trust the CEO; just do your DD on Dr Slilaty and you will understand why I trust him. Patience is key.
All IMO.
Question :
Why would directors of Sunshine newly acquire shares of the company (as announced recently) if they thought the SP would be dropping? They just must know something that we don't I presume. They bought in at 0.007. Let's see what happens.
Any opinions?
Regards.
Mr Brando:
Please understand that your posts have no credibility whatsoever. I'm not just saying this because you bash the stock...even when you were pumping it! I strongly suggest that you post something only when you have something intelligent to say - whether it's positive or negative.
Cheers.
Question :
How do we know for certain that institutional buyers are in?
Thanks in advance.
How can we tell that institutional buyers are coming?
Interesting read:
Biotech Investor Q&A with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products
New York, New York – July 16, 2012 – ( Investorideas.com Newswire ) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a Q&A
snapshot of two biotech companies taking aim at aggressive forms of cancer; Roche (SIX: RO, ROG; OTCQX: RHHBY) with its Herceptin® cancer drug and Sunshine Biopharma Inc. (OTCBB: SBFM) with its
lead compound, Adva-27a.
The interview(s) gives investors insight into how a small biotech company, Sunshine Biopharma, plans to
target the cancer drug market of the future with its technology and collaborations and the historical path of
the largest biotech company in the world bringing Herceptin® to market, reaching sales of over $5
billion in 2010.
Roche (SIX: RO, ROG; OTCQX: RHHBY) /Genetech’s Herceptin:
Q: Investorideas.com staff:
When was the licensing agreement put in place with Genentech and Roche for Herceptin®?
A: Nina Goworek, Investor Relations Officer for Roche
Genentech and Roche signed a licensing agreement giving Roche exclusive marketing rights for
Herceptin outside of the US in July 1998
Q: Investorideas.com staff:
What other cancers are targeted with Herceptin® other than HER2-positive breast cancer and what FDA
approvals are in place?
A: Nina Goworek, Investor Relations Officer for Roche
In the US:
September 1998 - Herceptin is approved for 1st-line Her2 positive metastatic breast cancer in
combination with chemotherapy (paclitaxel) and also approved as a medicine to be used alone for
women who had received prior chemotherapy (second- and third-line treatment),
November 2006 - Herceptin is approved for adjuvant or early stage HER2 positive breast cancer when
given with chemotherapy (doxorubicin, cyclophosphamide and paclitaxel), a combination called AC-TH
January 2008 - approved as a stand-alone medicine following anthracycline-based chemotherapy
May 2008 - Herceptin and chemotherapy (docetaxel and carboplatin), known as TCH, was approved;
Another AC-TH combination, comprised of Herceptin, doxorubicin, cyclophosphamide and docetaxel, was
also approved
October 2010 - Herceptin is approved in combination with cisplatin and capecitabine or 5-fluorouracil, for
the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction
adenocarcinoma, who have not received prior treatment for metastatic disease (1st-line)
Q: Investorideas.com staff:
The Company recently announced in June the FDA approved for Perjeta in combination with Herceptinhow
does this combination improve results?
A; Nina Goworek, Investor Relations Officer for Roche
The addition of Perjeta in combination with Herceptin plus docetaxel (chemo) showed an increase of
progression free survival (PFS) from a median of 12.4 months to 18.5 months - an increase of 6.1months.
Statistically significant overall survival top-line results were announced with the data to be presented at an
upcoming medical meeting.
Q: Investorideas.com staff:
What is the current number of women with HER2-positive breast cancer have been treated with
Herceptin?
A; Nina Goworek, Investor Relations Officer for Roche
As of January 2012, there were roughly 440,000 patients treated with Herceptin in the US for all
indications and more that 1.2 million people have been treated with Herceptin globally.
Sunshine Biopharma Inc. (OTCBB: SBFM) and Adva-27a[/u
Q: Investorideas.com
Can you give us a brief history of the development of Adva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
Adva-27a is a small molecule which we designed and synthesized de novo. The patents covering Adva-
27a and derivatives in the United States and Europe have issued recently. Various patents in other
places around the world are still pending. Adva-27a was designed to specifically target multidrug
resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
From your recent press releases you now have data on both lung and breast cancer results for Adva-27a,
potentially doubling the market potential. Can you give investors a brief summary of the results to date?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc.
There are different types of transporter proteins which when overexpressed make cancer cells resistant to
drugs. Different multidrug resistant cancer types may overexpress different transporter proteins. Our data
to date have shown that Adva-27a can overcome two multidrug resistance proteins: MDR1 and MRP1 as
present in the breast cancer cells and the lung cancer cells we tested. Lung and breast cancer are the
two most frequently encountered cancers in humans.
Q: Investorideas.com staff
How do your collaborations with the State University of New York at Binghamton and McGill University’s
Jewish General Hospital in Montreal (Canada) help you take Adva-27a to clinical trials?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We are delighted for the help, dedication and contribution of these two of the finest institutions in the
world. They have and continue to be of great help to us in our efforts to put Adva-27a through the drug
development stages. We anticipate that our first clinical trial will be done at the Jewish General Hospital
on breast cancer volunteers.
Q: Investorideas.com staff
For investors looking at a small biotech company like yours, taking on the big pharma companies, how do
you address the massive financial and corporate undertaking of bringing Adva-27a to market?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
It is indeed very costly to bring a drug to market. We have been fortunate in our financing efforts to date
and we hope to be able to continue to access the private and public markets for funding on an as needed
basis to continue the development of our flagship Adva-27a and bring it to market for cancer sufferers
around the world.
Q: Investorideas.com staff
Do you have any third party projections for the market potential of Adva-27a?
A: Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc
We have not commissioned any one to do projections of market potential of our Adva-27a. However, we
do know that important cancer drugs generally reach annual sales of about $1 billion within 1 to 2 years of
FDA approval. We believe Adva-27a will have a similar sales profile.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and
commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound,
Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About Roche (SIX: RO, ROG; OTCQX: RHHBY):
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined
strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly
differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the
world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes
management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools
that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche
had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group
posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the
Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
www.roche.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and
pharma stocks. Other sectors include renewable energy, oil and gas, mining and tech stocks.
Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make
recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites
should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com
for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed
companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com
I doubt it. If they wanted to make people buy, they wopuld at least bring the price steadily up. My question is who is selling all these shares ... and who is buying...
Can someone please explain how we have such volume, and just trading sideways...if someone was dumping then the price would really drop to sub penny levels with this volume. If someone was buying, we should have been higher. Thanks in advance.
Conclusion:
I do not think this man is out to screw investors:)
About Dr Slilaty:
Dr. Steve N. Slilaty Ph.D. has been the President, Chief Executive Officer and Chief Scientific Officer of Advanomics Corporation since February 2002. Dr. Slilaty has been the Chairman, Chief Executive Officer and President of Sunshine Biopharma, Inc. since October 15, 2009. He founded Qbiogene Inc. in 1991 and Genomics One Corporation in 1995. He served as Scientific Director at ALERT B&C Corporation. He was a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada. Dr. Slilaty served as a Consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997. He has been Member and Chairman of Scientific Advisory Board of Pacific Sunset Investments Inc. since May 17, 2005. He has been the Chairman of the Scientific Advisory Board at Gen-ID Lab Services Inc. since May 17, 2005. He serves as Director of Advanomics Corporation. Dr. Slilaty's other career accomplishments include elucidation of the molecular mechanism for cleavage of LexA, the repressor protein of the E. coli DNA repair system; developing the first site-directed mutagenesis system applicable directly to double-stranded DNA; cloning the gene for the first yeast-lytic enzyme (lytic B-1,3-glucanase); developing a new molecular strategy for increasing the rate of enzyme reactions; inventing the TrueBlue(R) Technology, a powerful new cloning system for accelerating gene discovery and, most recently, developing a new transcriptomics technology for generating entire RNA profiles. He serves as an Adjunct Professor at Universite du Quebec in the Department of Microbiology and Biotechnology. He is an accomplished scientist and a highly skilled business executive. He is cited worldwide and profiled in a variety of reference manuals. Dr. Slilaty is the author of eleven original research papers and four issued (5,071,743; 5,883,244; 6,127,171 and 6,500,619) and one pending (60/532,774) US patents. He has received research grants from the NIH and NSF. He is the recipient of the 1981 award from the University of Arizona Foundation for Meritorious Performance in Teaching. Dr. Slilaty and his vast knowledge of the human genome equips Pacific Sunset with an innovative chairman that can advise Pacific Sunset Investments Inc.'s officers, directors and employees on testing procedures of DNA samples, help better analyze results of the SNPs (SNiPs) studies, and provide overall support to insure the successful implementation of Gen ID's business plan. Dr. Slilaty received his Bachelors of Science degree in Genetics and Biochemistry from Cornell University in 1976 and his Ph.D. in Cell Biology and Biochemistry from the University of Arizona in 1983.
Forget who is buying...the question is who is selling at this point!